Use of Genome-Wide Protein Expression Libraries

全基因组蛋白质表达文库的使用

• 批准号: 6338142
• 负责人: JOHN J HARRINGTON
• 金额: $ 9.91万
• 依托单位: ATHERSYS, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-05-15 至 2002-05-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6338142
• 关键词: astrocytes; cell line; epidermal growth factor; functional /structural genomics; gene expression; genetic library; genome; high throughput technology; human genetic material tag; mitogens; molecular cloning; muscle cells; platelet derived growth factor; technology /technique development

DESCRIPTION (Applicant's abstract): We propose a novel high-throughput approach to the discovery of novel mitogens. We will use Random Activated Gene Expression (RAGE), which allows unbiased expression of full-length, or near full-length, transcripts of greater than 95 percent of the human genome in a library of only 5 million clones, to carry out a high throughput search for previously undiscovered mitogens. Our Phase I target populations will be conditionally immortal astrocytes and skeletal muscle cells, so as to reveal proteins of potential use in treatment of neuromuscular disease or CNS damage. The RAGE technology allows identification of the bioactive protein and large-scale production (e.g., 250 mg/liter) to be achieved within 10-14 weeks from the time of first identification of activity. Thus, this program also enables production of novel factors in sufficient quantity to support extensive biological analysis and commercial development. In addition to potential medical benefits, the discovery of new mitogens has considerable benefits on biological research in general. Even the limited number of growth factors available has provided a central foundation for, e.g., the nascent field of stem cell biology. Success in this Phase I program will enable a full-scale effort to rapidly identify novel mitogens for a wide range of cell types. PROPOSED COMMERCIAL APPLICATION: This project will enable the ready adaptation of the RAGE technology to virtually any functional genomics assay system, permitting the identification and characterization of a large number of novel proteins and genes that encode them. Thus not only will Athersys have a technology product but it will also have various therapeutic products that were identified by virtue of RAGE's use in an assay system.

描述（申请人的摘要）：我们提出了一种新颖的高通量方法 发现新颖的有丝分裂剂。我们将使用随机激活的基因 表达（愤怒），允许全长或靠近的无偏表达 全长，在A中大于95％的人类基因组的转录本 只有500万个克隆的库，可以进行高吞吐量搜索 以前未被发现的有丝分裂原。我们的目标人群将是 有条件永生的星形胶质细胞和骨骼肌细胞，以揭示 在治疗神经肌肉疾病或中枢神经系统损伤的潜在使用的蛋白质。 愤怒技术允许识别生物活性蛋白和 将在10-14周内实现大规模生产（例如250 mg/升） 从首次识别活动开始。因此，这个程序也 能够产生足够数量的新因素以支持广泛的因素 生物分析和商业发展。除了潜力 医疗益处，发现新有丝分裂剂对 一般的生物学研究。甚至有限的增长因素 可用为例如 干细胞生物学。在此阶段I计划中的成功将启用全面 努力快速识别各种细胞类型的新型有丝分裂原。 拟议的商业应用： 该项目将使RAGE技术现成的改编几乎可以适应任何功能 基因组学测定系统，允许大量识别和表征 编码它们的新型蛋白质和基因。 因此，Athersys不仅有技术 产品，但它还将拥有各种凭借的治疗产品 RAGE在测定系统中的使用。